Because Diabetes Mellitus is one of the major risk factors for CV disease and lots of related
evidences have been published including CARDS study that showed definite benefit of statin
treatment in DM patients and influenced ADA guideline. & NCEP ATP III update. However, there
are large unmet medical needs for DM patients who don't reach their target LDL-C level
defined NCEPT ATP III update because of physicians usually start with the lowest dose of
statin and then titrate to the goal. Thus, we are curious about changing our prescription
pattern into more tailored way; selecting starting dose based on the individual risk factors
and concomitant status will impact the goal achieving rate for DM patients. Besides that, we
are going to find out preliminary data about other markers change; small dense LDL and
adiponectine;. Small dense LDL-C is more inflammatory and atherogenic LDL-C that may explain
the impact of triglyceride. Adiponectin is another good marker related with obesity and
metabolic syndrome.